Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.

Autor: Levy AG, Zage PE, Akers LJ, Ghisoli ML, Chen Z, Fang W, Kannan S, Graham T, Zeng L, Franklin AR, Huang P, Zweidler-McKay PA

Publikováno v: Investigational New Drugs; Feb2012, Vol. 30 Issue 1, p191-199, 9p

A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.

Autor: Zage PE, Zeng L, Palla S, Fang W, Nilsson MB, Heymach JV, Zweidler-McKay PA, Zage, Peter E, Zeng, Lizhi, Palla, Shana, Fang, Wendy, Nilsson, Monique B, Heymach, John V, Zweidler-McKay, Patrick A

Publikováno v: Cancer (0008543X); 5/15/2010, Vol. 116 Issue 10, p2465-2475, 11p

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.

Autor: Hayashi RJ; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO., Hermiston ML; Pediatric Hematology Oncology, University of California, San Francisco, San Francisco, CA., Wood BL; Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA., Teachey DT; Division of Pediatric Oncology, Department of Pediatrics, Center for Childhood Cancer Research, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Devidas M; Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN., Chen Z; Department of Biostatistics, University of Florida, Gainesville, FL., Annett RD; Department of Pediatrics, University of New Mexico, Albuquerque, NM., Asselin BL; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Golisano Children's Hospital, University of Rochester, Rochester, NY., August K; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, MO., Cho S; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Wisconsin Institute for Medical Research, Madison, WI., Dunsmore KP; Department of Pediatrics, Virginia Tech Carilion School of Medicine, Roanoke, VA., Freedman JL; Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA., Galardy PJ; Department of Pediatric Hematology and Oncology, Mayo Clinic, Rochester, MN., Harker-Murray P; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Midwest Children's Cancer Center, Milwaukee, WI., Horton TM; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX., Jaju A; Division of Pediatric Radiology, Department of Radiology, Lurie Children's Hospital, Chicago, IL., Lam A; Miller Children's and Women's Hospital, Long Beach, CA., Messinger YH; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN., Miles RR; Division of Hematopathology, Department of Pathology, ARUP Institute for Clinical and Experimental Pathology, University of Utah, Primary Children's Hospital, Salt Lake City, UT., Okada M; Division of Radiation Oncology, Department of Oncology, University of Alberta-Stollery Children's Hospital, Edmonton, AB, Canada., Patel S; Division of Radiation Oncology, Department of Oncology, University of Alberta-Stollery Children's Hospital, Edmonton, AB, Canada., Schafer ES; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX., Schechter T; Division of Hematology/Oncology, Department of Pediatrics, University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada., Shimano KA; Department of Pediatrics, University of California Benioff Children's Hospital, San Francisco, CA., Singh N; Michigan State University Clinical Center, Lansing, MI., Steele A; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Carolinas Medical Center/Levine Cancer Institute, Charlotte, NC., Sulis ML; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY., Vargas SL; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Children's Oncology Group, Monrovia, CA., Winter SS; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Research Institute and Cancer and Blood Disorders Program, Children's Minnesota, Minneapolis, MN., Wood C; Department of Biostatistics, Children's Oncology Group Data Center, Gainesville, FL., Zweidler-McKay PA; ImmunoGen, Inc, Waltham, MA., Loh ML; Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Washington, Seattle, WA., Hunger SP; Division of Pediatric Oncology, Department of Pediatrics, Center for Childhood Cancer Research, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Raetz EA; Division of Pediatric Hematology and Oncology, Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders, NYU Langone Health, New York, NY., Bollard CM; Division of Blood and Bone Marrow Transplantation, Department of Pediatrics, Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC., Allen CE; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX.

Publikováno v: Blood [Blood] 2024 May 16; Vol. 143 (20), pp. 2053-2058.

miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.

Autor: Fuentes-Mattei E, Bayraktar R, Manshouri T, Silva AM, Ivan C, Gulei D, Fabris L, Soares do Amaral N, Mur P, Perez C, Torres-Claudio E, Dragomir MP, Badillo-Perez A, Knutsen E, Narayanan P, Golfman L, Shimizu M, Zhang X, Zhao W, Ho WT, Estecio MR, Bartholomeusz G, Tomuleasa C, Berindan-Neagoe I, Zweidler-McKay PA, Estrov Z, Zhao ZJ, Verstovsek S, Calin GA, Redis RS

Publikováno v: JCI insight [JCI Insight] 2024 Feb 08; Vol. 9 (3). Date of Electronic Publication: 2024 Feb 08.